Immune Checkpoint Inhibitor Toxicity Management Clinical Practice Guideline
Version:
1
mar 2018
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Guideline Objective
Immune checkpoint inhibitor medications are associated with unique immune-related adverse effects (irAEs) that can range from bothersome to life-threatening. Symptoms vary in their onset time, can progress quickly, and may occur months after treatment discontinuation. Early identification of irARs and appropriate management can improve patients’ quality of life and safety.
The objective of this guideline is to provide user-friendly guidance for the management of irAEs. It contains the following:
- A description of irAEs associated with immune checkpoint inhibitor medications.
- Practical guidance on the general management of irAEs.
- Detailed algorithms that describe the assessment and management of ten specific irAEs.
- General considerations for patients on immune checkpoint inhibitor medications.
Intended Guideline Users
All clinicians involved in the care of cancer patients who are receiving immune checkpoint inhibitor medications.
Full Report (PDF) (1.45 Mo)